Novel CoronaVirus Vaccines development - Jobs & Services

Published date: February 4, 2020
1.00 AED

Details of listing: Novel CoronaVirus Vaccines development

Additional information


The mysterious coronavirus outbreak in the Chinese city Wuhan and its fast spread across Asia, endangers thousands of lives. The pandemic has catalysed the development of novel vaccines across the biotech industry, both by pharmaceutical companies and research organisations such as the National Institutes of Health (NIH), US.

Follow the updates on coronavirus:
Coronavirus (2019-nCoV) outbreak in Wuhan

Coronavirus: timeline of events and latest updates

List of coronavirus suspected countries

Companies such as Inovio Pharmaceuticals, Moderna, and Novavax have been reported to be developing coronavirus vaccines. A total of 30 therapies are planned to be tested, including few traditional medicines, by Chinese scientists. Meanwhile, clinical-stage biotech company GeoVax signed a letter of intent with BravoVax, a vaccine developer based in Wuhan, China, to jointly develop a coronavirus vaccine using genetic sequences of the 2019-nCoV.

Here is a list of the major pipeline drugs that pharmaceutical companies across the world are developing that have the potential to become major coronavirus vaccines or antivirals for treating the contagious coronavirus infection.

Coronavirus vaccines
Novavax’s MERS coronavirus vaccine candidate
Novavax developed a novel Middle East Respiratory Syndrome (MERS) coronavirus vaccine candidate in 2013, post the identification of the first MERS coronavirus ((MERS-CoV) in Saudi Arabia in 2012. It is a crucial target for vaccine development by the Coalition for Epidemic Preparedness Innovations (CEPI) and is a priority disease for the World Health Organisation (WHO).
The UK leaves the European Union on 31 January. Do you think this will be a positive or a negative for the pharmaceutical industry?

Strongly positive
Slightly positive
Slightly negative
Strongly negative

View Results

The candidate is designed to primarily bind to the major surface spike (S) protein and developed using the company’s recombinant nanoparticle vaccine technology. Tested along with the Novavax’s proprietary adjuvant Matrix-M™, it inhibited infection by inducing immune responses in the laboratory studies.

The MERS coronavirus is related to the severe acute respiratory syndrome (SARS) coronavirus for which the company had previously developed a recombinant nanoparticle vaccine candidate.

Inovio Pharma’s INO-4700
The investigational DNA immunotherapy, INO-4700 (GLS-5300) is being developed by Inovio in partnership with GeneOne Life Science. It is delivered as vaccine intramuscularly, using the Cellectra® delivery device.

The vaccine was well-tolerated and demonstrated high immune responses against the MERS-CoV in 94% of patients in the early-stage clinical trial in July 2019.

It also generated broad-based T cell responses in 88% of the subjects.

“Research organisations such as the National Institutes of Health (NIH), US are also developing a vaccine for the coronavirus.”

Coronavirus medicines
Biocryst Pharma’s Galidesivir, a potential antiviral for coronavirus treatment
The antiviral drug Galidesivir (BCX4430) has shown broad-spectrum activity against a wide range of pathogens including coronavirus. It is a nucleoside RNA polymerase inhibitor that disrupts the process of viral replication.

The drug has already shown survival benefits in patients against deadly viruses such as Ebola, Zika, Marburg, and Yellow fever.

Galidesivir is currently in advanced development stage unde


    Leave your comment or feedback

    Image Gallery

    Contact publisher

    Name: Anonymous